Published in J Clin Oncol on May 01, 2006
High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. J Clin Oncol (2011) 2.28
Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer. Gut (2011) 2.21
Survival after hepatic resection of colorectal cancer metastases: a national experience. Cancer (2009) 1.81
The oncosurgery approach to managing liver metastases from colorectal cancer: a multidisciplinary international consensus. Oncologist (2012) 1.76
Predicting poor outcome following hepatectomy: analysis of 2313 hepatectomies in the NSQIP database. HPB (Oxford) (2009) 1.70
Selection for hepatic resection of colorectal liver metastases: expert consensus statement. HPB (Oxford) (2013) 1.50
Postoperative liver dysfunction and future remnant liver: where is the limit? Results of a prospective study. World J Surg (2007) 1.43
Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg (2007) 1.42
Treatment in advanced colorectal cancer: what, when and how? Br J Cancer (2009) 1.40
Histological and immediate postoperative outcome after preoperative cetuximab: case-matched control study. World J Surg (2010) 1.40
High risk of biliary fistula after isolated segment VIII liver resection. World J Surg (2012) 1.40
Current treatment for colorectal liver metastases. World J Gastroenterol (2011) 1.38
Histopathologic evaluation of liver metastases from colorectal cancer in patients treated with FOLFOXIRI plus bevacizumab. Br J Cancer (2013) 1.37
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer (2009) 1.25
Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol (2009) 1.24
Pathogenesis of FOLFOX induced sinusoidal obstruction syndrome in a murine chemotherapy model. J Hepatol (2013) 1.20
Surgery for colorectal liver metastases. Br J Cancer (2010) 1.19
Safe liver resection following chemotherapy for colorectal metastases is a matter of timing. Br J Cancer (2007) 1.16
Chemotherapy-associated liver injury in patients with colorectal liver metastases: a systematic review and meta-analysis. Ann Surg Oncol (2012) 1.15
Role of surgery in colorectal cancer liver metastases. World J Gastroenterol (2014) 1.13
Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres. Dig Dis Sci (2008) 1.12
Mechanistic patient-specific predictive correlation of tumor drug response with microenvironment and perfusion measurements. Proc Natl Acad Sci U S A (2013) 1.08
Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch (2011) 1.07
Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford) (2012) 1.07
2012 Liver resections in the 21st century: we are far from zero mortality. HPB (Oxford) (2013) 1.07
Optimal future liver remnant in patients treated with extensive preoperative chemotherapy for colorectal liver metastases. Ann Surg Oncol (2013) 1.05
The effects of cancer chemotherapy on liver imaging. Eur Radiol (2009) 1.04
Treatment of colorectal liver metastases. World J Surg Oncol (2011) 1.04
The pathological response to neoadjuvant chemotherapy with FOLFOX-4 for colorectal liver metastases: a comparative study. Virchows Arch (2007) 1.04
Two-stage strategy for patients with extensive bilateral colorectal liver metastases. HPB (Oxford) (2010) 1.04
Total intermittent Pringle maneuver during liver resection can induce intestinal epithelial cell damage and endotoxemia. PLoS One (2012) 1.03
New paradigm in the management of liver-only metastases from colorectal cancer. Gastrointest Cancer Res (2007) 1.03
Predictors of morbidity and mortality after hepatectomy in elderly patients: analysis of 7621 NSQIP patients. HPB (Oxford) (2013) 1.03
Toxicant-associated steatohepatitis in vinyl chloride workers. Hepatology (2010) 1.02
Standardized liver volumetry for portal vein embolization. Semin Intervent Radiol (2008) 1.01
Recent advances in the curative treatment of colorectal liver metastases. Gastrointest Cancer Res (2011) 1.00
The liver-first approach for synchronous colorectal liver metastasis: a 5-year single-centre experience. HPB (Oxford) (2011) 1.00
Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol (2009) 1.00
Body mass index and adverse perioperative outcomes following hepatic resection. J Gastrointest Surg (2010) 0.98
Preoperative imaging of colorectal liver metastases after neoadjuvant chemotherapy: a meta-analysis. Ann Surg Oncol (2012) 0.98
Therapeutic promise and challenges of targeting DLL4/NOTCH1. Vasc Cell (2011) 0.98
Practical questions in liver metastases of colorectal cancer: general principles of treatment. HPB (Oxford) (2007) 0.97
Colorectal cancer with liver metastases: neoadjuvant chemotherapy, surgical resection first or palliation alone? World J Gastroenterol (2014) 0.97
Liver-directed therapies in metastatic colorectal cancer. J Gastrointest Oncol (2014) 0.97
Chinese guidelines for the diagnosis and comprehensive treatment of hepatic metastasis of colorectal cancer. J Cancer Res Clin Oncol (2011) 0.95
The surgical treatment of hepatic metastases in colorectal carcinoma. Dtsch Arztebl Int (2010) 0.95
Techniques of hepatic resection. J Gastrointest Oncol (2012) 0.95
Neoadjuvant treatment of colorectal liver metastases is associated with altered contrast enhancement on computed tomography. Cancer Imaging (2011) 0.94
Two-stage hepatectomy (R0) with portal vein ligation--towards curing patients with extended bilobular colorectal liver metastases. Int J Colorectal Dis (2008) 0.93
Treatment for colorectal liver metastases: a review. Langenbecks Arch Surg (2009) 0.93
Colorectal liver metastases. Int J Surg Oncol (2011) 0.93
Liver injury induced by anticancer chemotherapy and radiation therapy. Int J Hepatol (2013) 0.93
Repeat hepatectomy for recurrent colorectal liver metastases is associated with a high survival rate. HPB (Oxford) (2011) 0.93
Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases. Ann Surg Oncol (2010) 0.92
Remnant growth rate after portal vein embolization is a good early predictor of post-hepatectomy liver failure. J Am Coll Surg (2014) 0.91
Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis. HPB (Oxford) (2010) 0.91
Anatomical versus nonanatomical resection of colorectal liver metastases: is there a difference in surgical and oncological outcome? World J Surg (2011) 0.91
[Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines]. Pathologe (2010) 0.90
Early arterial stasis during resin-based yttrium-90 radioembolization: incidence and preliminary outcomes. HPB (Oxford) (2013) 0.90
Prognostic scores for colorectal liver metastasis: clinically important or an academic exercise? HPB (Oxford) (2010) 0.90
Impact of preoperative bevacizumab on complications after resection of colorectal liver metastases: case-matched control study. World J Surg (2010) 0.90
Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy. Int J Clin Oncol (2011) 0.88
Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified? Cancer (2011) 0.88
Interaction of tumour biology and tumour burden in determining outcome after hepatic resection for colorectal metastases. HPB (Oxford) (2010) 0.88
Simultaneous laparoscopic resection of primary colorectal cancer and associated liver metastases: a systematic review. Tech Coloproctol (2013) 0.87
Colorectal liver metastasis surgery: analysis of risk factors predicting postoperative complications in relation to the extent of resection. Int J Colorectal Dis (2009) 0.87
Metastatic colorectal cancer outcome and fatty liver disease. Nat Rev Gastroenterol Hepatol (2013) 0.87
Contrast-enhanced 3D ultrasound in the radiofrequency ablation of liver tumors. World J Gastroenterol (2009) 0.86
Hypertrophy of the non-embolized liver after chemotherapy. HPB (Oxford) (2009) 0.86
Perioperative management of hepatic resection. J Gastrointest Oncol (2012) 0.86
Effect of metabolic syndrome on perioperative outcomes after liver surgery: A National Surgical Quality Improvement Program (NSQIP) analysis. Surgery (2012) 0.86
Assessment of the reporting of quality and outcome measures in hepatic resections: a call for 90-day reporting in all hepatectomy series. HPB (Oxford) (2015) 0.86
Ninety-day Postoperative Mortality Is a Legitimate Measure of Hepatopancreatobiliary Surgical Quality. Ann Surg (2015) 0.86
Multisciplinary management of patients with liver metastasis from colorectal cancer. World J Gastroenterol (2016) 0.85
Adjuvant chemotherapy for resected colorectal cancer metastases: Literature review and meta-analysis. World J Gastroenterol (2016) 0.85
Neoadjuvant FOLFIRI+bevacizumab in patients with resectable liver metastases from colorectal cancer: a phase 2 trial. Br J Cancer (2013) 0.85
A phase II experience with neoadjuvant irinotecan (CPT-11), 5-fluorouracil (5-FU) and leucovorin (LV) for colorectal liver metastases. BMC Cancer (2009) 0.85
Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research. Prog Lipid Res (2015) 0.84
Risk factors for early recurrence after curative hepatectomy for colorectal liver metastases. Surg Today (2011) 0.84
Sinusoidal obstruction syndrome compromises liver regeneration in patients undergoing two-stage hepatectomy with portal vein embolization. Surg Today (2010) 0.83
Influence of preoperative chemotherapy on the intraoperative and postoperative course of liver resection for colorectal cancer metastases. World J Surg (2012) 0.83
Staging of colorectal liver metastases after preoperative chemotherapy. Diffusion-weighted imaging in combination with Gd-EOB-DTPA MRI sequences increases sensitivity and diagnostic accuracy. Eur Radiol (2012) 0.83
Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases. PLoS One (2014) 0.83
An experimental study to identify the potential role of pharmacogenomics in determining the occurrence of oxaliplatin-induced liver injury. HPB (Oxford) (2012) 0.82
Portal vein embolization: rationale, technique, and current application. Semin Intervent Radiol (2012) 0.82
Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges? World J Hepatol (2014) 0.82
Mechanistic review of drug-induced steatohepatitis. Toxicol Appl Pharmacol (2015) 0.82
Multi-modality treatment of colorectal liver metastases. World J Gastroenterol (2012) 0.82
Patient selection for hepatic resection for metastatic colorectal cancer. J Gastrointest Oncol (2012) 0.82
mRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury. HPB (Oxford) (2011) 0.82
The effect of hepatic steatosis on survival following resection of colorectal liver metastases in patients without preoperative chemotherapy. HPB (Oxford) (2012) 0.81
Update and review of the multidisciplinary management of stage IV colorectal cancer with liver metastases. World J Surg Oncol (2009) 0.81
Chemotherapy within 30 days prior to liver resection does not increase postoperative morbidity or mortality. HPB (Oxford) (2009) 0.81
The role of S-adenosylmethionine in preventing oxaliplatin-induced liver toxicity: a retrospective analysis in metastatic colorectal cancer patients treated with bevacizumab plus oxaliplatin-based regimen. Support Care Cancer (2011) 0.81
The role of peri-operative chemotherapy for resectable colorectal liver metastasis: what does the evidence support? J Gastrointest Surg (2011) 0.80
Using a 'no drain' policy in 342 laparoscopic hepatectomies: which factors predict failure? HPB (Oxford) (2013) 0.80
Limiting factors for liver regeneration after a major hepatic resection for colorectal cancer metastases. HPB (Oxford) (2013) 0.80
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol (2008) 15.05
Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature (2003) 10.33
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med (2004) 9.80
ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol (2012) 9.76
Consensus statement on the pathology of IgG4-related disease. Mod Pathol (2012) 9.01
Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers. Sci Transl Med (2012) 8.41
Functional genomics reveal that the serine synthesis pathway is essential in breast cancer. Nature (2011) 8.03
Mst1 and Mst2 maintain hepatocyte quiescence and suppress hepatocellular carcinoma development through inactivation of the Yap1 oncogene. Cancer Cell (2009) 7.39
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res (2009) 7.35
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg (2004) 6.75
Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology (2002) 6.62
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes Dev (2006) 5.53
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol (2009) 5.42
The international position on laparoscopic liver surgery: The Louisville Statement, 2008. Ann Surg (2009) 5.33
Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. Ann Surg (2005) 4.86
Pathology of genetically engineered mouse models of pancreatic exocrine cancer: consensus report and recommendations. Cancer Res (2006) 4.83
EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov (2012) 4.72
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol (2008) 4.68
International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas (2011) 4.56
Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol (2006) 4.50
Posthepatectomy liver failure: a definition and grading by the International Study Group of Liver Surgery (ISGLS). Surgery (2011) 4.40
Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nat Genet (2011) 4.38
Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol (2008) 4.37
Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg (2007) 4.09
Cystic neoplasms of the pancreas. N Engl J Med (2004) 3.89
Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery (2012) 3.87
A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov (2011) 3.86
Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol (2007) 3.85
Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol (2005) 3.83
Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology (2007) 3.78
Once-only sigmoidoscopy in colorectal cancer screening: follow-up findings of the Italian Randomized Controlled Trial--SCORE. J Natl Cancer Inst (2011) 3.75
Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin Cancer Res (2006) 3.65
Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc (2012) 3.60
Analysis of fluorouracil-based adjuvant chemotherapy and radiation after pancreaticoduodenectomy for ductal adenocarcinoma of the pancreas: results of a large, prospectively collected database at the Johns Hopkins Hospital. J Clin Oncol (2008) 3.51
mTORC1 in the Paneth cell niche couples intestinal stem-cell function to calorie intake. Nature (2012) 3.51
Simplified staging for hepatocellular carcinoma. J Clin Oncol (2002) 3.48
Comparison of CT methods for determining the fat content of the liver. AJR Am J Roentgenol (2007) 3.45
Acquired resistance to crizotinib from a mutation in CD74-ROS1. N Engl J Med (2013) 3.42
Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol (2009) 3.39
Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell (2012) 3.39
Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg (2008) 3.36
Optical coherence tomography to identify intramucosal carcinoma and high-grade dysplasia in Barrett's esophagus. Clin Gastroenterol Hepatol (2006) 3.28
MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib. J Clin Oncol (2011) 3.27
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. Ann Surg Oncol (2009) 3.22
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery. Surgery (2011) 3.16
Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell (2005) 3.15
Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg (2009) 3.15
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol (2012) 3.02
Baseline findings of the Italian multicenter randomized controlled trial of "once-only sigmoidoscopy"--SCORE. J Natl Cancer Inst (2002) 3.00
Human bile contains microRNA-laden extracellular vesicles that can be used for cholangiocarcinoma diagnosis. Hepatology (2014) 2.98
A clinical outcome-based prospective study on venous thromboembolism after cancer surgery: the @RISTOS project. Ann Surg (2006) 2.97
Branch-duct intraductal papillary mucinous neoplasms: observations in 145 patients who underwent resection. Gastroenterology (2007) 2.96
Comprehensive microscopy of the esophagus in human patients with optical frequency domain imaging. Gastrointest Endosc (2008) 2.94
Mammalian pharmacokinetics of carbon nanotubes using intrinsic near-infrared fluorescence. Proc Natl Acad Sci U S A (2006) 2.91
Multicenter phase III study of uracil/tegafur and oral leucovorin versus fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol (2002) 2.89
Combined resection and radiofrequency ablation for advanced hepatic malignancies: results in 172 patients. Ann Surg Oncol (2003) 2.85
Comparison of a lymph node ratio-based staging system with the 7th AJCC system for gastric cancer: analysis of 18,043 patients from the SEER database. Ann Surg (2012) 2.85
Carbon nanotube-enhanced thermal destruction of cancer cells in a noninvasive radiofrequency field. Cancer (2007) 2.83
Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene (2003) 2.79
Imaging-based quantification of hepatic fat: methods and clinical applications. Radiographics (2009) 2.79
Case records of the Massachusetts General Hospital. Case 31-2006. A 15-year-old girl with severe obesity. N Engl J Med (2006) 2.71
Self-reported conflicts of interest of authors, trial sponsorship, and the interpretation of editorials and related phase III trials in oncology. J Clin Oncol (2013) 2.68
Drastic down-regulation of Krüppel-like factor 4 expression is critical in human gastric cancer development and progression. Cancer Res (2005) 2.67
Case records of the Massachusetts General Hospital. Case 23-2005. A 57-year-old man with a mass in the liver. N Engl J Med (2005) 2.67
Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann Surg Oncol (2006) 2.66
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer. Clin Cancer Res (2013) 2.65
Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res (2009) 2.62
Pancreaticoduodenectomy with vascular resection: margin status and survival duration. J Gastrointest Surg (2004) 2.62
Extended hepatectomy in patients with hepatobiliary malignancies with and without preoperative portal vein embolization. Arch Surg (2002) 2.62
Hepatic insufficiency and mortality in 1,059 noncirrhotic patients undergoing major hepatectomy. J Am Coll Surg (2007) 2.62